Consensus Alvotech

Stocks

ALVO

LU2458332611

Biotechnology & Medical Research

End-of-day quote Nasdaq 17/09/2026			5-day change	1st Jan Change
5.340 ^USD	+4.71%		+0.95%	+4.09%

18/09	Nordic stocks in North America, Ericsson fell 0.4 percent	FW
17/09	Alvotech Shares Rise After Double Upgrade From Barclays	MT

Evolution of the Average Target: Alvotech

Evolution of the Target Price: Alvotech

Changes in Analyst Recommendations: Alvotech

ced5.I7O6UfcMyEPwAf5IcLHf5S2hilSD8HJohwYaS2WC000.EILuIoNkggSfVLMOSfWGs3yW6DHIqAE3_3RVBwOv4SZmgc0QlkuEBaZlkQ~a33bf67da57d0ada53a3228f91aa68e8

Analysts' recommendations: Alvotech

17/09	Alvotech Shares Rise After Double Upgrade From Barclays	MT
16/09	Barclays Upgrades Alvotech to Overweight From Underweight, Adjusts PT to $8 From $4	MT
25/08	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says	MT
24/08	BofA Securities Initiates Alvotech at Buy With $7 Price Target	MT
25/03	UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating	MT
24/03	Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating	MT
22/12	Stockholm Bullets - Viscaria Soars on Buy Recommendation	FW
19/11	UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating	MT
05/11	Alvotech Shares Fall After Deutsche Bank Downgrade	MT
05/11	Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14	MT
04/11	Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14	MT
04/11	Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar	DJ
04/11	Top Premarket Decliners	MT
03/11	Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell	MT
03/11	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05	CI
15/10/25	Alvotech Shares Rise After Morgan Stanley Upgrade	MT
14/10/25	Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14	MT
24/09/25	Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says	MT
23/09/25	Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14	MT
21/07/25	UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal	MT
18/07/25	UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating	MT
26/07/24	Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating	MT
25/05/24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
23/03/24	Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	MT
29/01/24	Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALVOTECH					+27.34%
	LONZA GROUP AG					+26.27%
	IQVIA HOLDINGS INC.					+3.16%
	REVOLUTION MEDICINES, INC.					+27.56%
	BEONE MEDICINES AG					+22.45%
	CELLTRION, INC.					+49.02%
	MEDPACE HOLDINGS, INC.					-5.42%
	ASCENDIS PHARMA A/S					+30.8%
	EUROFINS SCIENTIFIC SE					-6.03%
	ICON PUBLIC LIMITED COMPANY					+9.18%
	Average					+18.43%
	Weighted average by Cap.					+20.12%